Advances in local targeted gene therapy for arthritis: Towards clinical reality

Future Rheumatology

Volumn 3, Issue 4, 2008, Pages 307-309

  Vervoordeldonk, Margriet J ^a   Aalbers, Caroline J ^a   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PARVOVIRUS VECTOR; RECOMBINANT BETA INTERFERON; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY;

CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG SAFETY; EDITORIAL; GENE THERAPY; HEMOPHILIA B; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID;

EID: 55649110855     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.3.4.307     Document Type: Editorial

References (14)

1. Vervoordeldonk MJ, Adriaansen J, Fallaux FF, Tak PP: Gene therapy for rheumatoid arthritis. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 6, 109-120 (2007).
2. Evans C: Arthritis gene therapy at an inflection point. Future Rheumatol. 3(3) 207-210 (2008).
3. Qu g, Bahr-Davidson J, Prado J et al.: Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography. J. Virol. Methods 140(1-2), 183-192 (2007).
4. Mingozzi F, High KA: Immune responses to AAV in clinical trials. Curr. Gene Ther. 7(5), 316-324 (2007).
5. Mingozzi F, Meulenberg J, Hui D et al.: T cell responses to capsid in AAV-1-mediated gene transfer to skeletal muscle. Mol. Ther. 16(Suppl. 1), S162 (2008).
6. Kaplitt MG, Feigin A, Tang C et al.: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, Phase I trial. Lancet 369(9579), 2097-2105 (2007).
7. Kaiser J: Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 318(5856), 1535 (2007).
8. Adriaansen J, Tas SW, Klarenbeek PL et al.: Enhanced gene transfer to arthritic joint using adeno-associated virus type 5: implications for intra-articular gene therapy. Ann. Rheum. Dis. 64(12), 1677-1684 (2005).
9. Apparailly F, Khoury M, Vervoordeldonk MJ et al.: Adeno-associated virus pseudotype 5 vector improves gene transfer in arthritic joints. Hum. Gene Ther. 16(4), 426-434 (2005).
10. Tak PP: IFN-β in rheumatoid arthritis. Front. Biosci. 1 (9), 3242-3247 (2004).
11. Adriaansen J, Kuhlman RR, van Holten J. Kaynor C, Vervoordeldonk MJ, Tak PP: Intraarticular interferon-β gene therapy ameliorates adjuvant arthritis in rats. Hum. Gene Ther. 17(10), 985-996 (2006).
12. Adriaansen J, Fallaux FJ, de Cortie CJ, Vervoordeldonk MJ. Tak PP: Local delivery of β interferon using an adeno-associated virus type 5 effectively inhibits adjuvant arthritis in rats. J. Gen. Virol. 88(6). 1717-1721 (2007).
13. Gerlag DM, Tak PP: Novel approaches for the treatment of rheumatoid arthritis: lessons from the evaluation of synovial biomarkers in clinical trials. Best Pract. Res. Clin. Rheumatol. 22(2), 311-323 (2008).
14. Anklesaria P, Heald AE, Mease PJ; 13G01Study Group: Intra-articular administration of a recombinant adeno-associated vector containing a TNF antagonist gene was safe, well tolerated and demonstrated trend in clinical response in subjects with inflammatory arthritis. Mol. Ther. 16(Suppl. 1), S111 (2008).